Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
NCT Number: NCT04213196
This is a first-in-human, Phase I, single-dose escalation clinical trial conducted in Chinese healthy volunteers. The safety, tolerability, and PK of HSK21542 injection in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Hangzhou, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
Other names: HSK21542 0.2 μg/kg
Time frame: From screening up to 3 weeks
Adverse event/serious adverse event
Time frame: From screening up to 3 weeks
Vital signs (Systolic and Diastolic Blood Pressure) will be collected in healthy volunteers.
Time frame: -60 minutes before administration until 24 hours after administration
Ramsay sedation score will be collected
Time frame: from administration to 24 hours after administration
VAS addiction score will be collected
Time frame: -30 minutes before administration until 24 hours after administration
Cmax(a measure of the body's exposure to HSK21542)will be calculated in healthy volunteers.
Time frame: -30 minutes before administration until 24 hours after administration
AUC(a measure of the body's exposure to HSK21542)will be calculated in healthy volunteers.
Time frame: -30 minutes before administration until 24 hours after administration
time to peak observed
Time frame: -30 minutes before administration until 24 hours after administration
Total clearance
Time frame: before administration until 24 hours after administration
Prolactin level will be collected
Time frame: before administration until 24 hours after administration
Antidiuretic hormone level will be collected
Time frame: before administration until 24 hours after administration
Urine volume will be collected
Sichuan Haisco Pharmaceutical Group Co., Ltd
Industry
A Phase I Clinical Study Evaluating the Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial DetailsNCT07090655
Healthy Volunteers
Brisbane, Australia
View Trial DetailsNCT01915212
Communicable Diseases, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details